Cargando…

Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients

Microbiological diagnosis by using commercial multiplex quantitative PCR systems provides great advantages over the conventional culture. In this work, the Biofire FilmArray Pneumonia Panel Plus (FAPP+) was used to test 144 low respiratory tract samples from 105 COVID-19 patients admitted to an Inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Escudero, Dolores, Fernández-Suarez, Jonathan, Forcelledo, Lorena, Balboa, Salvador, Fernández, Javier, Astola, Ivan, Quindos, Brigida, Campos, Rainer, Vázquez, Fernando, Boga, José Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777407/
https://www.ncbi.nlm.nih.gov/pubmed/36553141
http://dx.doi.org/10.3390/diagnostics12123134
_version_ 1784856096009093120
author Escudero, Dolores
Fernández-Suarez, Jonathan
Forcelledo, Lorena
Balboa, Salvador
Fernández, Javier
Astola, Ivan
Quindos, Brigida
Campos, Rainer
Vázquez, Fernando
Boga, José Antonio
author_facet Escudero, Dolores
Fernández-Suarez, Jonathan
Forcelledo, Lorena
Balboa, Salvador
Fernández, Javier
Astola, Ivan
Quindos, Brigida
Campos, Rainer
Vázquez, Fernando
Boga, José Antonio
author_sort Escudero, Dolores
collection PubMed
description Microbiological diagnosis by using commercial multiplex quantitative PCR systems provides great advantages over the conventional culture. In this work, the Biofire FilmArray Pneumonia Panel Plus (FAPP+) was used to test 144 low respiratory tract samples from 105 COVID-19 patients admitted to an Intensive Care Unit (ICU), detecting 78 pathogens in 59 (41%) samples. The molecular panel was evaluated by using the conventional culture (CC) as comparator, which isolated 42 pathogens in 40 (27.7%) samples. The overall percentage of agreement was 82.6%. Values of sensitivity (93%), specificity (62%), positive predictive value (50%), and negative predictive value (96%) were obtained. The mean time elapsed from sample extraction to modification of antibiotic treatment was 7.6 h. A change in antimicrobial treatment after the FAPP+ results was performed in 27% of patients. The FAPP+ is a highly sensitive diagnostic method that can be used to significantly reduce diagnostic time and that allows an early optimization of antimicrobial treatment.
format Online
Article
Text
id pubmed-9777407
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97774072022-12-23 Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients Escudero, Dolores Fernández-Suarez, Jonathan Forcelledo, Lorena Balboa, Salvador Fernández, Javier Astola, Ivan Quindos, Brigida Campos, Rainer Vázquez, Fernando Boga, José Antonio Diagnostics (Basel) Article Microbiological diagnosis by using commercial multiplex quantitative PCR systems provides great advantages over the conventional culture. In this work, the Biofire FilmArray Pneumonia Panel Plus (FAPP+) was used to test 144 low respiratory tract samples from 105 COVID-19 patients admitted to an Intensive Care Unit (ICU), detecting 78 pathogens in 59 (41%) samples. The molecular panel was evaluated by using the conventional culture (CC) as comparator, which isolated 42 pathogens in 40 (27.7%) samples. The overall percentage of agreement was 82.6%. Values of sensitivity (93%), specificity (62%), positive predictive value (50%), and negative predictive value (96%) were obtained. The mean time elapsed from sample extraction to modification of antibiotic treatment was 7.6 h. A change in antimicrobial treatment after the FAPP+ results was performed in 27% of patients. The FAPP+ is a highly sensitive diagnostic method that can be used to significantly reduce diagnostic time and that allows an early optimization of antimicrobial treatment. MDPI 2022-12-12 /pmc/articles/PMC9777407/ /pubmed/36553141 http://dx.doi.org/10.3390/diagnostics12123134 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Escudero, Dolores
Fernández-Suarez, Jonathan
Forcelledo, Lorena
Balboa, Salvador
Fernández, Javier
Astola, Ivan
Quindos, Brigida
Campos, Rainer
Vázquez, Fernando
Boga, José Antonio
Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients
title Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients
title_full Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients
title_fullStr Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients
title_full_unstemmed Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients
title_short Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients
title_sort evaluation and clinical impact of biofire filmarray pneumonia panel plus in icu-hospitalized covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777407/
https://www.ncbi.nlm.nih.gov/pubmed/36553141
http://dx.doi.org/10.3390/diagnostics12123134
work_keys_str_mv AT escuderodolores evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients
AT fernandezsuarezjonathan evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients
AT forcelledolorena evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients
AT balboasalvador evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients
AT fernandezjavier evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients
AT astolaivan evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients
AT quindosbrigida evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients
AT camposrainer evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients
AT vazquezfernando evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients
AT bogajoseantonio evaluationandclinicalimpactofbiofirefilmarraypneumoniapanelplusinicuhospitalizedcovid19patients